AZN FY 2009 Earnings Report — AstraZeneca PLC Revenue & Financial Results | Market Cap Arena

AstraZeneca PLCAZN

FY 2009 Earnings

Reported December 30, 2009

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2009	Prior Q	FY 2008	QoQ Change	YoY Change
Revenue	$32.8B	—	—	—	—
Op. Income	$11.5B	—	—	—	—
Gross Margin	82.4%	—	—	—	—
Net Margin	22.9%	—	—	—	—
EPS (Diluted)	$10.38	—	—	—	—
Free Cash Flow	$8.8B	—	—	—	—

Revenue Flow

Item	Amount
REVENUE	$32.8B
Cost of Revenue	$5.8B
GROSS PROFIT	$27.0B
R&D Expenses	$4.4B
Selling & Marketing	$298M
General & Administrative	$11.3B
SG&A Expenses	$11.6B
Other Expenses	-$553M
Operating Expenses	$15.5B
Cost & Expenses	$21.3B
OPERATING INCOME	$11.5B
Interest Income	$462M
Interest Expense	$1.1B
Other Income/Expenses	-$736M
INCOME BEFORE TAX	$10.8B
Income Tax Expense	$3.3B
Net Income from Continuing Ops	$7.5B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$7.5B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$7.5B
D&A	$2.1B
EBIT	$11.9B
EBITDA	$13.9B
EPS	$10
EPS Diluted	$10

Income Statement

Item	Amount
REVENUE	$32.8B
Cost of Revenue	$5.8B
GROSS PROFIT	$27.0B
R&D Expenses	$4.4B
Selling & Marketing	$298M
General & Administrative	$11.3B
SG&A Expenses	$11.6B
Other Expenses	-$553M
Operating Expenses	$15.5B
Cost & Expenses	$21.3B
OPERATING INCOME	$11.5B
Interest Income	$462M
Interest Expense	$1.1B
Other Income/Expenses	-$736M
INCOME BEFORE TAX	$10.8B
Income Tax Expense	$3.3B
Net Income from Continuing Ops	$7.5B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$7.5B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$7.5B
D&A	$2.1B
EBIT	$11.9B
EBITDA	$13.9B
EPS	$10
EPS Diluted	$10

Cash Flow Statement

Item	Amount
Net Income	$7.5B
Depreciation & Amortization	$2.1B
Stock-Based Compensation	$0
Deferred Income Tax	$0
Other Non-Cash Items	$802M
Change in Working Capital	$1.3B
OPERATING CASH FLOW	$11.7B
Capital Expenditure	-$3.0B
Acquisitions (Net)	-$217M
Purchases of Investments	-$31M
Sales/Maturities of Investments	$3M
Other Investing Activities	$726M
NET CASH FROM INVESTING	-$2.5B
Net Debt Issuance	-$787M
Common Stock Repurchased	$0
Common Dividends Paid	-$3.0B
Other Financing Activities	$0
NET CASH FROM FINANCING	-$3.6B
FREE CASH FLOW	$8.8B
Net Change in Cash	$5.7B

Balance Sheet

Item	Amount
Cash & Equivalents	$9.9B
Short-Term Investments	$1.5B
Net Receivables	-$24M
Inventory	$1.8B
Other Current Assets	$9.9B
TOTAL CURRENT ASSETS	$23.8B
PP&E (Net)	$7.3B
Goodwill	$9.9B
Intangible Assets	$12.2B
Long-Term Investments	-$1.3B
Tax Assets	$1.3B
Other Non-Current Assets	$1.8B
TOTAL NON-CURRENT ASSETS	$31.2B
TOTAL ASSETS	$54.9B
Account Payables	$2.7B
Short-Term Debt	$1.9B
Deferred Revenue	$6.9B
Other Current Liabilities	$3.7B
TOTAL CURRENT LIABILITIES	$17.6B
Long-Term Debt	$9.4B
Deferred Revenue NC	-$5.3B
Deferred Tax Liabilities	$3.2B
Other Non-Current Liabilities	$3.8B
TOTAL NON-CURRENT LIABILITIES	$16.5B
TOTAL LIABILITIES	$34.1B
Common Stock	$363M
Additional Paid-In Capital	$2.2B
Retained Earnings	$16.2B
Treasury Stock	$0
Accum. Other Comp. Income	$0
Other Equity	$1.9B
TOTAL STOCKHOLDERS' EQUITY	$20.7B
Minority Interest	$161M
TOTAL EQUITY	$20.8B
TOTAL LIABILITIES & EQUITY	$54.9B
Total Debt	$11.3B
Net Debt	$1.4B